Denali Therapeutics Inc.
Income Statement
| Line Item | Jun 2026 | Jun 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M | $0 | $0 | $0 | $0 | $0 | $0 | $1.3M |
| Cost of Revenue | $93.0K | $0 | — | — | — | — | — | — |
| Gross Profit | $3.5M | $0 | — | — | — | — | — | — |
| Gross Margin | 97.4% | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $97.0M | $102.7M | $99.8M | $98.2M | $91.4M | $107.0M | $107.8M | $89.7M |
| SG&A Expense | $36.3M | $32.3M | $30.1M | $24.9M | $25.2M | $25.2M | $24.8M | $25.3M |
| Operating Income | $-130.5M | $-135.0M | $-129.8M | $-123.2M | $-116.6M | $-117.7M | $-132.6M | $-113.8M |
| Operating Margin | -3,622.1% | — | — | — | — | — | — | -8,981.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | $0 |
| Net Income | $-127.6M | $-124.1M | $-114.8M | $-107.2M | $-99.0M | $-101.8M | $-119.5M | $-99.4M |
| Net Margin | -3,539.2% | — | — | — | — | — | — | -7,841.6% |
| EPS (Basic) | $-0.68 | $-0.72 | $-0.67 | $-0.63 | $-0.59 | $-0.68 | $-0.88 | $-0.72 |
| EPS (Diluted) | $-0.68 | $-0.72 | $-0.67 | $-0.63 | $-0.59 | $-0.68 | $-0.84 | $-0.72 |
| Shares Outstanding (Basic) | 187.3M | 171.4M | 164.5M | 169.5M | 168.8M | 149.4M | 137.4M | 137.6M |
| Shares Outstanding (Diluted) | 187.3M | 171.4M | 164.5M | 169.5M | 168.8M | 149.4M | 137.4M | 137.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |